Approval

Five things for pharma marketers to know: Thursday, October 19, 2017

Five things for pharma marketers to know: Thursday, October 19, 2017

By

The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence

Five things for pharma marketers to know: Friday, September 29, 2017

Five things for pharma marketers to know: Friday, September 29, 2017

By

Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards

Five things for pharma marketers to know: Monday, September 25, 2017

Five things for pharma marketers to know: Monday, September 25, 2017

By

The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine

Five things for pharma marketers to know: Friday, September 15, 2017

Five things for pharma marketers to know: Friday, September 15, 2017

By

The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops

Five things for pharma marketers to know: Wednesday, August 30, 2017

Five things for pharma marketers to know: Wednesday, August 30, 2017

By

Nonprofits receive FDA approval for Chagas drug; Gilead's buyout of Kite will put it back in pricing fray; most cancer patients don't receive fertility info

Five things for pharma marketers to know: Monday, August 21, 2017

Five things for pharma marketers to know: Monday, August 21, 2017

The FDA approves Ironwood's gout drug; GSW names new president; Samsung and Takeda to partner on biologic development

Five things for pharma marketers to know: Friday, August 4, 2017

Five things for pharma marketers to know: Friday, August 4, 2017

By

AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch

Five things for pharma marketers to know: Friday, July 14, 2017

Five things for pharma marketers to know: Friday, July 14, 2017

By

The FDA approves J&J psoriasis drug; PARP inhibitors are not cost-effective, ICER says; Verily releases mosquitoes to combat Zika

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Five things for pharma marketers to know: Wednesday, May 10, 2017

Five things for pharma marketers to know: Wednesday, May 10, 2017

By

The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study

Five things for pharma marketers to know: Monday, May 1, 2017

Five things for pharma marketers to know: Monday, May 1, 2017

By

The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

By

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Five things for pharma marketers to know: Thursday, April 6, 2017

Five things for pharma marketers to know: Thursday, April 6, 2017

By

The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers

Why President Trump Won't Overhaul the FDA

Why President Trump Won't Overhaul the FDA

In short, the Trump team, I predict, will seek to tweak FDA.

Five things for pharma marketers to know: Thursday, February 16, 2017

Five things for pharma marketers to know: Thursday, February 16, 2017

By

The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents

A Reformed FDA Under Trump Likely Means Uncertainty

A Reformed FDA Under Trump Likely Means Uncertainty

It's hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

By

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Five things for pharma marketers to know: Tuesday, January 3, 2017

Five things for pharma marketers to know: Tuesday, January 3, 2017

By

The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000

Five things for pharma marketers to know: Wednesday, December 14, 2016

Five things for pharma marketers to know: Wednesday, December 14, 2016

By

Obama signs 21st Century Cures Act into law; the FDA approved 19 new drugs in 2016; Sanofi in talks to acquire Actelion

Five things for pharma marketers to know: Thursday, November 3, 2016

Five things for pharma marketers to know: Thursday, November 3, 2016

By

Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients

The FDA approves Amgen's biosimilar version of Humira

The FDA approves Amgen's biosimilar version of Humira

By

Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.

Five things for pharma marketers to know: Tuesday, September 20, 2016

Five things for pharma marketers to know: Tuesday, September 20, 2016

By

GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck

Five things for pharma marketers to know: Friday, September 16, 2016

Five things for pharma marketers to know: Friday, September 16, 2016

By

The FDA approves a combination of aspirin and heartburn medication; Teva partners with Intel to develop wearable; New Mexico AG sues BMS and Sanofi

Five things for pharma marketers to know: Wednesday, July 20, 2016

Five things for pharma marketers to know: Wednesday, July 20, 2016

By By

Spending on CME rose in 2015; the FDA approves Valeant's Relistor; the Justice Department aims to block insurer merger

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Five things for pharma marketers to know: Wednesday, February 3, 2016

Five things for pharma marketers to know: Wednesday, February 3, 2016

By

Seven potential blockbusters set to launch in 2016; Amarin case may lead to 'misleading' marketing; Valeant, Turing raised prices to meet preset targets

Speeding up FDA Approvals Calls for Pause

Speeding up FDA Approvals Calls for Pause

The idea that 30 days is enough time for the FDA to evaluate anything is, of course, quite silly. But Sen. Cruz takes it one step further.

Five things for pharma marketers to know: Friday, January 15, 2016

By

The FDA declines to approve two drugs for Duchenne muscular dystrophy; government watchdog questions FDA's post-market drug tracking; WebMD denies acquisition talks

Five things for pharma marketers to know: Monday, January 4, 2016

Five things for pharma marketers to know: Monday, January 4, 2016

By

The FDA approved 45 new drugs in 2015; Baxalta signs immuno-oncology deal; pharma M&A activity may slow this year

Five things for pharma marketers to know: Tuesday, December 29, 2015

Five things for pharma marketers to know: Tuesday, December 29, 2015

By

Generic-drug approval backlog criticized; KaloBios board members step down; Sovaldi costs as little as $4 in India